Could the endocannabinoid system hold clues for treating bipolar disorder?
A review of clinical and molecular evidence suggests the endocannabinoid system may play a role in bipolar disorder, with CB2 receptor activation emerging as a potential mood-stabilizing target.
Quick Facts
What This Study Found
The endocannabinoid system exerts neuromodulatory effects on neurotransmitter systems critical for emotion regulation. Limited clinical and molecular evidence suggests ECS dysfunction may contribute to bipolar disorder pathophysiology, with selective CB2 receptor agonists showing potential for mood stabilization.
Key Numbers
No specific numerical outcomes reported. The review highlights that the ECS role in BD has been "almost neglected" in research despite available data suggesting mood regulation involvement.
How They Did This
Perspective review synthesizing clinical, molecular, and anecdotal evidence on the relationship between the endocannabinoid system and bipolar disorder.
Why This Research Matters
Bipolar disorder remains inadequately treated in a significant subset of patients. If ECS manipulation can stabilize mood, it would open an entirely new class of treatment targets for a condition with limited pharmacological options.
The Bigger Picture
Cannabis use is common among people with bipolar disorder, often as self-medication. Understanding the ECS-mood connection could explain both the appeal and the risks of cannabis use in this population, and potentially lead to targeted cannabinoid therapies.
What This Study Doesn't Tell Us
The available data on ECS and bipolar disorder is very limited. The CB2 mood stabilization hypothesis is based on indirect evidence rather than clinical trials. Cannabis use in BD also carries risks including triggering manic episodes.
Questions This Raises
- ?Could selective CB2 agonists stabilize mood without the risks associated with cannabis use?
- ?What are the specific ECS alterations in bipolar disorder versus healthy controls?
- ?Would targeting the ECS help treatment-resistant BD patients?
Trust & Context
- Key Stat:
- CB2 receptors as mood target
- Evidence Grade:
- Rated preliminary because the evidence linking the ECS to bipolar disorder is mostly indirect and no clinical trials of cannabinoid-based BD treatments have been conducted.
- Study Age:
- Published in 2019. Research on endocannabinoid involvement in mood disorders has continued to develop.
- Original Title:
- Bipolar disorder and the endocannabinoid system.
- Published In:
- Acta neuropsychiatrica, 31(4), 193-201 (2019)
- Authors:
- Arjmand, Shokouh(2), Behzadi, Mina(3), Kohlmeier, Kristi A(2), Mazhari, Shahrzad, Sabahi, Abdolreza, Shabani, Mohammad
- Database ID:
- RTHC-01918
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Does cannabis help bipolar disorder?
The evidence is too limited to say. This review found theoretical reasons why the endocannabinoid system could be involved in mood regulation, but cannabis use in bipolar disorder also carries risks including triggering manic episodes.
What is the CB2 receptor hypothesis?
The authors propose that activating CB2 cannabinoid receptors (which do not produce psychoactive effects like CB1) could help stabilize mood in bipolar disorder. This is based on indirect evidence and has not been tested in clinical trials.
Read More on RethinkTHC
Cite This Study
https://rethinkthc.com/research/RTHC-01918APA
Arjmand, Shokouh; Behzadi, Mina; Kohlmeier, Kristi A; Mazhari, Shahrzad; Sabahi, Abdolreza; Shabani, Mohammad. (2019). Bipolar disorder and the endocannabinoid system.. Acta neuropsychiatrica, 31(4), 193-201. https://doi.org/10.1017/neu.2019.21
MLA
Arjmand, Shokouh, et al. "Bipolar disorder and the endocannabinoid system.." Acta neuropsychiatrica, 2019. https://doi.org/10.1017/neu.2019.21
RethinkTHC
RethinkTHC Research Database. "Bipolar disorder and the endocannabinoid system." RTHC-01918. Retrieved from https://rethinkthc.com/research/arjmand-2019-bipolar-disorder-and-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.